A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/20 (2006.01) A61K 31/7088 (2006.01) A61K 35/14 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2513350
Provided herein are methods for treating CD127-low multiple sclerosis in a patient. A method may comprise administering to the patient an effective amount of at least one of: IL-7; leukocytes that have been treated with IL-7; leukocytes that have been induced to increase their cell surface expression of at least one receptor, a subunit of which is CD127; a nucleic acid molecule encoding at least CD127; TSLP; leukocytes that have been treated with TSLP; a non- functional form or homologue of IL-7 or TSLP; a soluble form of the IL-7 receptor; or an inhibitor of one or more of: IL-7, TSLP, CD127, CD132, the TSLP-R chain, the IL-7 receptor, or the TSLP receptor. Also provided are compositions for treating CD127-low multiple sclerosis. A composition comprises at least one pharmaceutically acceptable carrier, diluent and/or adjuvant and may further comprise at least one of: IL-7; leukocytes; TSLP; a non- functional form of IL-7; a non-functional homologue of IL-7; a soluble isoform of CD127; at least one inhibitor of one of IL-7, TSLP, CD127, CD132, the TSLP-R chain, the IL-7 receptor or the TSLP receptor. Also provided are methods for diagnosing or characterising a multiple sclerosis subtype in an individual or for determining the susceptibility of an individual to multiple sclerosis.
Booth David R.
Stewart Graeme John
Smart & Biggar
Sydney West Area Health Service
LandOfFree
Treatment for multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1947293